Author

Andreas Evers

Computational and Structural Bioinformatics, Merck KGaA - Cited by 2,211 - Drug Discovery

Biography

An experienced Drug Discovery scientist. Historically working on small molecules and, since 2010, responsible for the rational design and multi-parameter optimization of therapeutic peptides and proteins. Research activities include planning and coordination of early activity and physico-chemical characterization studies, update and application of different in silico models and in particular the continuous design of new molecules with the desired properties.
Title
Cited by
Year
Structure-based drug discovery using GPCR homology modeling: successful virtual screening for antagonists of the alpha1A adrenergic receptor
A Evers, T KlabundeJournal of medicinal chemistry 48 (4), 1088-1097, 2005200
313
2005
Virtual screening of biogenic amine-binding G-protein coupled receptors: comparative evaluation of protein-and ligand-based virtual screening protocols
A Evers, G Hessler, H Matter, T KlabundeJournal of medicinal chemistry 48 (17), 5448-5465, 2005200
227
2005
Successful virtual screening for a submicromolar antagonist of the neurokinin-1 receptor based on a ligand-supported homology model
A Evers, G KlebeJournal of medicinal chemistry 47 (22), 5381-5392, 2004200
205
2004
Recent progress and future options in the development of GLP-1 receptor agonists for the treatment of diabesity
M Lorenz, A Evers, M WagnerBioorganic & medicinal chemistry letters 23 (14), 4011-4018, 2013201
158
2013
Comparison of structure‐and ligand‐based virtual screening protocols considering hit list complementarity and enrichment factors
DM Krüger, A EversChemMedChem: Chemistry Enabling Drug Discovery 5 (1), 148-158, 2010201
133
2010
Ligand‐supported homology modeling of G‐protein‐coupled receptor sites: models sufficient for successful virtual screening
A Evers, G KlebeAngewandte Chemie International Edition 43 (2), 248-251, 2004200
130
2004
GPCR antitarget modeling: pharmacophore models for biogenic amine binding GPCRs to avoid GPCR‐mediated side effects
T Klabunde, A EversChemBioChem 6 (5), 876-889, 2005200
109
2005
Design of novel exendin-based dual glucagon-like peptide 1 (GLP-1)/glucagon receptor agonists
A Evers, T Haack, M Lorenz, M Bossart, R Elvert, B Henkel, S Stengelin, ...Journal of medicinal chemistry 60 (10), 4293-4303, 2017201
94
2017
Sequence-derived three-dimensional pharmacophore models for G-protein-coupled receptors and their application in virtual screening
T Klabunde, C Giegerich, A EversJournal of medicinal chemistry 52 (9), 2923-2932, 2009200
70
2009
Effects on weight loss and glycemic control with SAR441255, a potent unimolecular peptide GLP-1/GIP/GCG receptor triagonist
M Bossart, M Wagner, R Elvert, A Evers, T Hübschle, T Kloeckener, ...Cell metabolism 34 (1), 59-74. e10, 2022202
69
2022
Multiple-ligand-based virtual screening: methods and applications of the MTree approach
G Hessler, M Zimmermann, H Matter, A Evers, T Naumann, T Lengauer, ...Journal of medicinal chemistry 48 (21), 6575-6584, 2005200
52
2005
Dual glucagon-like peptide 1 (GLP-1)/glucagon receptor agonists specifically optimized for multidose formulations
A Evers, M Bossart, S Pfeiffer-Marek, R Elvert, H Schreuder, M Kurz, ...Journal of medicinal chemistry 61 (13), 5580-5593, 2018201
42
2018
Selective non-lipid modulator of LPA5 activity in human platelets
DH Kozian, A Evers, P Florian, P Wonerow, S Joho, M NazareBioorganic & medicinal chemistry letters 22 (16), 5239-5243, 2012201
36
2012
Novel small molecule inhibitors of activated thrombin activatable fibrinolysis inhibitor (TAFIa) from natural product anabaenopeptin
N Halland, M Brönstrup, J Czech, W Czechtizky, A Evers, M Follmann, ...Journal of Medicinal Chemistry 58 (11), 4839-4844, 2015201
35
2015
The Potential of P1 Site Alterations in Peptidomimetic Protease Inhibitors as Suggested by Virtual Screening and Explored by the Use of C C‐Coupling Reagents
S Weik, T Luksch, A Evers, J Böttcher, CA Sotriffer, A Hasilik, HG Löffler, ...ChemMedChem: Chemistry Enabling Drug Discovery 1 (4), 445-457, 2006200
35
2006
Identification of High-Affinity P2Y12 Antagonists Based on a Phenylpyrazole Glutamic Acid Piperazine Backbone
G Zech, G Hessler, A Evers, T Weiss, P Florian, M Just, J Czech, ...Journal of Medicinal Chemistry 55 (20), 8615-8629, 2012201
30
2012
Running on mixed fuel‐dual agonistic approach of GLP‐1 and GCG receptors leads to beneficial impact on body weight and blood glucose control: a comparative study between mice …
R Elvert, AW Herling, M Bossart, T Weiss, B Zhang, P Wenski, ...Diabetes, Obesity and Metabolism 20 (8), 1836-1851, 2018201
29
2018
Incretin combination therapy for the treatment of non‐alcoholic steatohepatitis
A Kannt, AN Madsen, C Kammermeier, R Elvert, T Klöckener, M Bossart, ...Diabetes, Obesity and Metabolism 22 (8), 1328-1338, 2020202
25
2020
Peptide optimization at the drug discovery-development interface: tailoring of physicochemical properties toward specific formulation requirements
A Evers, S Pfeiffer-Marek, M Bossart, C Heubel, U Stock, G Tiwari, ...Journal of Pharmaceutical Sciences 108 (4), 1404-1414, 2019201
22
2019
Modulation of hexadecyl‐LPA‐mediated activation of mast cells and microglia by a chemical probe for LPA5
DH Kozian, E von Haeften, S Joho, W Czechtizky, UR Anumala, P Roux, ...Chembiochem 17 (9), 861-865, 2016201
21
2016

Referred From: https://scholar.google.com/citations?user=ZwPWLosAAAAJ&hl=en

Cited by
Citations 2211
h-index 21
i10-index 31
Open Access Journals